GlaxoSmith’s net profits surged by 5% during 9MCY19

Sep-19

Sep-18

% Change

Net sales

                   11,812,260,072

                   10,856,290,137

8.81%

Cost of sales

                   (8,026,525,766)

                   (7,342,466,967)

9.32%

Gross profit

                     3,785,734,306

                     3,513,823,170

7.74%

Selling, marketing and distribution expenses

                   (2,138,610,379)

                   (1,930,640,388)

10.77%

Administrative expenses

                      (185,675,547)

                      (215,548,177)

-13.86%

Other operating expenses

                      (101,571,312)

                         (99,365,233)

2.22%

Other income

                           41,895,328

                         123,499,398

-66.08%

Operating profit/(loss)

                     1,401,772,396

                     1,391,768,770

0.72%

Financial cost

                      (163,252,105)

                      (207,572,857)

-21.35%

Profit/(loss) before taxation

                     1,238,520,291

                     1,184,195,913

4.59%

Taxation

                      (350,178,072)

                      (338,243,495)

3.53%

Profit/(loss) after taxation

                         888,342,219

                         845,952,418

5.01%

Earnings per share - basic and diluted (Rupees)

                                        7.59

                                        7.23

4.98%